Can the Cytokine Profile According to ABO Blood Groups Be Related to Worse Outcome in COVID-19 Patients? Yes, They Can

• DOI: 10.3389/fimmu.2021.726283
• Publication Date: 2021-10-13T18:14:33Z
• Authors: Álvaro Tamayo-Vel...; María Jesús Peñar...; Francisco Javier ...; Hugo Gonzalo-Benito; Ignacio de la Fuente; Sonia Pérez-González; Lucía Rico; María Teresa Jimé...; Alba Sánchez Rodr...; Milagros Hijas Vi...; Marta Martín-Fern...; Carlos Dueñas; Esther Gómez-Sánchez; María Heredia-Rod...; Óscar Gorgojo-Gal...; Itziar Fernández; Lourdes del Río; Irene Carnicero-F...; María Fe Muñoz-Mo...; Eduardo Tamayo; David Bernardo; Pedro Martínez-Paz
• Keywords: Male; Immunology; http://metadata.un.org/sdg/3; Severity of Illness Index; ABO Blood-Group System; 03 medical and health sciences; Citoquinas; Humans; Prospective Studies; Mortality; Ensure healthy lives and promote well-being for all at all ages; Aged; Hepatocyte growth factor; 0303 health sciences; Hepatocyte Growth Factor; SARS-CoV-2; COVID-19; RC581-607; ABO blood groups; Middle Aged; Prognosis; mortality; COVID-19 (Enfermedad); Respiration, Artificial; Survival Analysis; cytokines; 3. Good health; Hospitalization; hepatocyte growth factor; Mortalidad; Disease Progression; Cytokines; Female; Immunologic diseases. Allergy; Biomarkers

Severe status of coronavirus disease 2019 (COVID-19) is extremely associated to cytokine release. Moreover, it has been suggested that blood group also with the prevalence and severity this disease. However, relationship between profile remains unclear in COVID-19 patients. In sense, we prospectively recruited 108 patients March April 2020 divided according ABO group. For analysis 45 cytokines, plasma samples were collected time admission hospital ward or intensive care unit at sixth day after admission. The results show there was a risk more than two times lower mechanical ventilation death O (log rank: p = 0.042). At first time, all statistically significant levels, except from hepatocyte growth factor, higher meanwhile second showed drop, 20% 40%. contrast, A/B/AB presented maintenance levels during time. Hepatocyte factor association intubation mortality non-O (OR: 4.229, 95% CI (2.064–8.665), < 0.001) only one bad prognosis biomarker 8.852, (1.540–50.878), 0.015). Therefore, are better outcome